Stock Price Quote

JUBILANT PHARMOVA LTD.

NSE : JUBLPHARMABSE : 530019ISIN CODE : INE700A01033Industry : Pharmaceuticals & DrugsHouse : Jubilant Bhartia
BSE1150.053.9 (+0.34 %)
PREV CLOSE ( ) 1146.15
OPEN PRICE ( ) 1169.10
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 8410
TODAY'S LOW / HIGH ( )1142.95 1171.60
52 WK LOW / HIGH ( )319.3 1247
NSE1150.354 (+0.35 %)
PREV CLOSE( ) 1146.35
OPEN PRICE ( ) 1152.05
BID PRICE (QTY) 1150.35 (273)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 144100
TODAY'S LOW / HIGH( ) 1142.45 1170.00
52 WK LOW / HIGH ( )318.75 1247.15
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 21-06 1978
Management Info
Shyam S Bhartia - Chairman Priyavrat Bhartia - Managing Director
Registered Office

Address Bhartiagram ,Jyotiba Phoolay Nagar, ,
Gajraula,
Uttar Pradesh-244223

Phone 05924-267437

Email invstors@jubl.com

Website www.jubilantpharmova.com

Registrars Details
Alankit Assignments Ltd.
205-208 , Anarkali Complex,Jhandewala Extension,,New Delhi
Listing : BSE, NSE

NEWS

10Oct Jubilant Pharmova informs about deleti
In reference to the Company’s disclosure dated July 27, 2024 filed under..
20Sep Jubilant Pharmova informs about disclo
Jubilant Pharmova has informed that it enclosed disclosure under Regulat..
10Sep Jubilant Pharmova’s arm gets VAI class
Jubilant Pharmova’s step down subsidiary -- Jubilant HollisterStier LLC..
19Aug Jubilant Pharmova’s step down arm sign
Jubilant Pharmova’s wholly owned subsidiary -- Jubilant Biosys’ (JBL) su..
09Aug Jubilant Pharmova informs about AGM no
Pursuant to Regulations 30 and 34 of the SEBI (Listing Obligations and D..

Financials

in Millions
QTR Jun 24 ANNUAL 24
Net Profit-102316
Gross Profit -112 417
Operating Profit 2071199
Net Sales 16677847

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

SMS Lifesciences (BSE)
peergroup  1560.35 (5.00%)
M.Cap ( in Cr)471.74
Pfizer (BSE)
peergroup  5838.70 (1.27%)
M.Cap ( in Cr)26710.73
Divi's Lab (BSE)
peergroup  6212.85 (1.17%)
M.Cap ( in Cr)164931.65
Alkem Laboratories (BSE)
peergroup  6247.25 (1.11%)
M.Cap ( in Cr)74695.24
Dr. Reddy's Lab (BSE)
peergroup  6664.65 (0.96%)
M.Cap ( in Cr)111217.64

Shareholding Pattern

PROMOTERS 50.68%
NON-INSTITUTION 25.77%
MUTUAL FUNDS/UTI 2.25%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Jubilant Pharmova Ltd.

Jubilant Pharmova Ltd. was incorporated in the year 1978. Its today's share price is 1150.05. Its current market capitalisation stands at Rs 18318.13 Cr. In the latest quarter, company has reported Gross Sales of Rs. 7847 Cr and Total Income of Rs.8881 Cr. The company's management includes Ramakrishnan Arul, Naresh Kapoor, Shivpriya Nanda, Harsh Mahajan, Shirish G Belapure, Arun Seth, Vivek Mehra, Sushil Kumar Roongta, Arvind Chokhany, Arjun Shanker Bhartia, Priyavrat Bhartia, Hari S Bhartia, Shyam S Bhartia.

It is listed on the BSE with a BSE Code of 530019 , NSE with an NSE Symbol of JUBLPHARMA and ISIN of INE700A01033. It's Registered office is at Bhartiagram ,Jyotiba Phoolay Nagar, Gajraula-244223, Uttar Pradesh. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, KN Gutgutia & Co, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.